We thank Susini and colleagues for their comments1  to our article on the risk of a new cancer in patients with chronic myeloproliferative neoplasms (CMPNs).2  We have read the results from their CMPN cohort from Tuscany with interest. We agree that any novel finding must be confirmed before generally accepted and shared with patients. However, other studies have found results in line with ours. Fallah et al reported an increased risk of kidney cancer, melanoma and nonmelanoma skin cancer, as well as endocrine cancers among patients diagnosed with polycythemia vera (PV).3  Nielsen et al reported an increased risk of any cancer among JAK2 V617F mutation-positive persons from the general population.4  In their study most new malignancies were CMPNs but also solid tumors were reported.4  Although we cannot rule out an effect of diagnostic misclassification of CMPNs in our study it is reassuring that we found similar risk of a new cancer among patients with chronic myeloid leukemia (CML) among whom diagnostic misclassification seems unlikely. We also found the expected increased risks of new hematologic malignancies. Furthermore, our results were robust across stratification according to a previous or current diagnosis of chronic obstructive pulmonary disease. The excess risk of nonhematologic cancers in our study is modest, ranging from 1.2 to 1.6, and might only be detectable in larger studies.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Henrik Frederiksen, Odense University Hospital Sdr, Boulevard 29, DK-5000 Odense C, Denmark; e-mail: hef@dadlnet.dk.

1
Susini
 
MC
Masala
 
G
Antonioli
 
E
, et al. 
Risk of second cancers in chronic myeloproliferative neoplasms.
Blood
2012
, vol. 
119
 
16
(pg. 
3861
-
3862
)
2
Frederiksen
 
H
Farkas
 
DK
Christiansen
 
CF
Hasselbalch
 
HC
Sorensen
 
HT
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.
Blood
2011
, vol. 
118
 
25
(pg. 
6515
-
6520
)
3
Fallah
 
M
Kharazmi
 
E
Sundquist
 
J
Hemminki
 
K
Higher risk of primary cancers after polycythaemia vera and vice versa [published online ahead of print January 31, 2012].
Br J Haematol
 
4
Nielsen
 
C
Birgens
 
HS
Nordestgaard
 
BG
Kjaer
 
L
Bojesen
 
SE
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
Haematologica
2011
, vol. 
96
 
3
(pg. 
450
-
453
)

Sign in via your Institution